About Us

About PanXome

PanXome is a software technology company with a platform which enables a broader spectrum of drug discovery than conventional computer-aided drug discovery tools.  The platform is grounded in a unique approach to building predictive models of druggable protein targets, based on homology and ligand similarity.  The platform is computationally efficient and currently covers 97% of the human exome, which opens a heretofore inaccessible region of target exploration and the ability to predict off-target interactions.

TARGET Discovery and ID

• Identification of protein targets responsible for disease mechanism of action
• Deconvolution of targets responsible for both on-target and off-target effects
• Method includes computational inference and forward chemical genomics
• Precomputed database of predictive binding models for 97% of the human exome

LEAD IDENTIFICATION

• Average hit rate of 24% in top 100 predictions
• 24X better than competing algorithms
• No requirement for experimental structures
• Higher quality compounds moving through hit-finding to lead-identification
• Screening covers 97% of human proteome
• Uses distant evolutionarily relationships and local pocket similarity to identify ligands
• Does not require any known ligand binding information to achieve comparable hit rates
• Can screen 22 million compounds/per hour on a single CPU Core

DRUG DE-RISKING

• Probability of passing a Phase 1 safety trial with 80% precision and recall
• Prioritized list of side effects ranked by severity
• List of proteins causing the side effects
• Design away from the severe side effects based on the off-target protein pocket properties
• Applicable to all small molecules including natural products

DRUG REPURPOSING

• Repurpose drugs that are on the market  to treat new diseases
• Repurpose drugs that have failed efficacy to target new proteins and diseases to rescue the asset
• Identify new target proteins associated with diseases with 30% precision